BEAM
NASDAQBeam Therapeutics Inc.
Price$23.49-0.45 (-1.88%)
01:30 PM07:45 PM
News · 26 weeks34+33%
2026-04-192026-10-11
Mix1490d
- Other5(36%)
- Insider4(29%)
- Earnings2(14%)
- SEC Filings2(14%)
- Leadership1(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Beam Therapeutics Inc.4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- PRBeam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressBEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present initial data from the ongoing Phase 1/2 clinical trial evaluating BEAM-301 for th
- INSIDERSVP, Finance and Treasurer Cavanagh Bethany J sold $4,565 worth of shares (187 units at $24.41) as part of a pre-agreed trading plan, decreasing direct ownership by 0.37% to 50,984 units (SEC Form 4) (for tax liability)4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Beam Therapeutics Inc.4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- PRBeam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corresponding Decrease in Toxic Circulating Z-polymers Safety Profile of BEAM-302 Remains Consistent with LNP-based Therapies Dosing Underway in Global Pivotal Cohort Designed to Support Potential U.
- PRBeam Therapeutics Appoints Eric Foster as Chief Commercial OfficerCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches. "Eric is an exceptional biopharmaceutical leader with a proven track record of building high-performing commercial organizations in specialty and rare disease markets," said John Evans, chief executive officer of Beam Therapeutics. "His decades of
- PRBeam Therapeutics to Participate in Upcoming September 2026 Investor ConferencesCAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in BostonCiti’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New YorkCantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York The live webcasts will be available in the investor section of the company's website at www
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
- SECSEC Form 10-Q filed by Beam Therapeutics Inc.10-Q - Beam Therapeutics Inc. (0001745999) (Filer)
- SECBeam Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Beam Therapeutics Inc. (0001745999) (Filer)
- PRBeam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU) Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029 CAMBRIDGE, Mass., Aug. 04, 2026
- INSIDERChief Medical Officer Simon Amy sold $429,037 worth of shares (16,667 units at $25.74) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 85,696 units (SEC Form 4)4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- PRBeam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026, taking place September 5–9, 2026, in Barcelona, Spain. BEAM-302 is Beam’s lead genetic disease program designed to be a best-in-class and first-in-class liver-targeting therapy for AATD that addresses the underlying pathophysiology of both liver and lung disease. "There remains a significant need for new trea
- INSIDERChief Medical Officer Simon Amy sold $12,954 worth of shares (373 units at $34.73) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 102,363 units (SEC Form 4) (withholding tax)4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERCEO Evans John M. exercised 50,000 shares at a strike of $0.90 and sold $1,745,037 worth of shares (50,000 units at $34.90) as part of a pre-agreed trading plan (SEC Form 4)4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSee Remark 1 Fmr Llc sold $10,039,492 worth of shares (284,860 units at $35.24) (SEC Form 4)4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERPresident Ciaramella Giuseppe exercised 35,505 shares at a strike of $0.96, increasing direct ownership by 16% to 253,911 units (SEC Form 4)4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- PRBeam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug AdministrationBEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging FDA Guidance for Accelerated Development of Genome Editing Therapies New Preclinical Data for BEAM-304 to be Presented at FASEB Genome Engineering: Research and Applications Conference CAMBRIDGE, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) applic
- SECBeam Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Beam Therapeutics Inc. (0001745999) (Filer)
- INSIDERSEC Form 4 filed by Director Maraganore John4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Director Walsh Kathleen E4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Director Shaw Christi4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Director Guindo Chirfi4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Director Cooper Graham K4 - Beam Therapeutics Inc. (0001745999) (Issuer)
BEAM FAQ
7 questionsWhat does Beam Therapeutics Inc. do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders...Where does BEAM stock trade?
Beam Therapeutics Inc. (BEAM) is listed on NASDAQ.What sector and industry is BEAM in?
Beam Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Beam Therapeutics Inc. go public?
Beam Therapeutics Inc. (BEAM) completed its IPO in 2020.What are analysts saying about BEAM?
Beam Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-02-20. Recent price targets range from $3900.00 to $4200.00.What companies are similar to BEAM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare BEAM side-by-side with any of them on Quantisnow.How can I track BEAM on Quantisnow?
Quantisnow aggregates Beam Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BEAM to receive live email and push alerts on every new disclosure.